View Older Stories View More Recent Stories

Mar 23, 2022 08:30AM Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
Mar 23, 2022 08:30AM Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
Mar 10, 2022 08:31AM Allogene Therapeutics (ALLO) Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
Mar 10, 2022 08:30AM Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
Mar 10, 2022 08:30AM Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
Mar 1, 2022 08:30AM Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report
Mar 1, 2022 08:30AM Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report
Feb 23, 2022 04:02PM Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Feb 23, 2022 04:02PM Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Feb 16, 2022 08:30AM Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
Feb 16, 2022 08:30AM Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
Jan 26, 2022 08:30AM Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
Jan 26, 2022 08:30AM Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
Jan 11, 2022 08:04AM Allogene Therapeutics (ALLO) Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR Technology
Jan 11, 2022 08:00AM Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
Jan 11, 2022 08:00AM Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
Jan 10, 2022 08:35AM Allogene Therapeutics (ALLO) Announces Removal of FDA Clinical Hold on AlloCAR T Trials
Jan 10, 2022 08:30AM Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
Jan 10, 2022 08:30AM Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
Jan 4, 2022 08:30AM Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
Jan 4, 2022 08:30AM Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
Dec 15, 2021 08:30AM Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
Dec 15, 2021 08:30AM Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
Dec 13, 2021 11:00AM Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of H
Dec 13, 2021 11:00AM Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of H
Dec 13, 2021 10:31AM Allogene Therapeutics (ALLO) Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma
Dec 13, 2021 10:30AM Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Dec 13, 2021 10:30AM Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Dec 1, 2021 08:30AM Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
Dec 1, 2021 08:30AM Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
Nov 12, 2021 08:30AM Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
Nov 12, 2021 08:30AM Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
Nov 4, 2021 04:02PM Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update  
Nov 4, 2021 04:02PM Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update  
Nov 4, 2021 09:05AM Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of Hematology
Nov 4, 2021 09:05AM Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of Hematology
Oct 28, 2021 08:30AM Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021
Oct 28, 2021 08:30AM Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021
Oct 7, 2021 04:16PM Allogene Therapeutics (ALLO) Announces FDA puts Clinical Hold on AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
Oct 7, 2021 04:15PM Allogene Therapeutics (ALLO) Announces FDA Clinical Hold of AlloCAR T Trials Based on Single Patient Case in ALPHA2 Trial
Oct 7, 2021 04:15PM Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
Oct 7, 2021 04:15PM Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
Sep 20, 2021 08:30AM Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board
Sep 20, 2021 08:30AM Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board
Sep 1, 2021 08:30AM Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Sep 1, 2021 08:30AM Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Aug 12, 2021 08:32AM Allogene Therapeutics (ALLO) Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma
Aug 12, 2021 08:30AM Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
Aug 12, 2021 08:30AM Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
Aug 4, 2021 04:02PM Allogene Therapeutics Reports Second Quarter 2021 Financial Results
View More Recent Stories View Older Stories